Ascendis Pharma A/S
ASND
164 hedge funds and large institutions have $6.54B invested in Ascendis Pharma A/S in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 65 reducing their positions, and 37 closing their positions.
413% more call options, than puts
Call options by funds: $117M | Put options by funds: $22.8M
8.86% less ownership
Funds ownership: 115.61% → 106.75% (-8.9%)
11% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 65
12% less funds holding
Funds holding: 187 → 164 (-23)
19% less capital invested
Capital invested by funds: $8.05B → $6.54B (-$1.51B)
35% less funds holding in top 10
Funds holding in top 10: 20 → 13 (-7)
57% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 37
Top Buyers
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$605M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$85.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$38.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.5M |
ASND Hedge Fund Activity: Q1 2023 in Review
164 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2023, worth a combined $6.54B — down 19% from $8.05B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ASND and 16 opened new positions — a net loss of 21 holders — while 65 trimmed existing stakes and 58 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $73.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $605M sold.
- 164 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2023, down from 187 in Q4 2022.
- Funds reported $6.54B of Ascendis Pharma A/S stock for Q1 2023, down 19% quarter-over-quarter.
- 16 funds opened new Ascendis Pharma A/S positions in Q1 2023 and 37 closed out, a net change of -21 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $73.8M added.
- The largest Ascendis Pharma A/S seller in Q1 2023 was Baker Bros. Advisors, an estimated $605M sold.
Based on aggregated 13F filings for Q1 2023.